Responses appear to occur in a tumor-agnostic fashion and have been described in NRG1 fusion-bearing lung, cholangiocarcinoma, ovarian, and pancreatic cancers, suggesting that malignancies harboring NRG1 fusions merit further investigation for another tissue-agnostic approval [67, 87]. This evidence concerns the gene NRG1 and familial pancreatic carcinoma.